SCY-078

DRUG6 trials

Sponsors

Scynexis, Inc.

Conditions

Candida VulvovaginitisCandidemiaCandidiasis, InvasiveInvasive Pulmonary AspergillosisMycosesVulvovaginal Candidiasis

Phase 2

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

CompletedNCT02244606

Scynexis, Inc.Candidemia, Candidiasis, Invasive, Mycoses

Start: 2014-09-30End: 2016-08-31Updated: 2024-06-25

Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

CompletedNCT02679456

Scynexis, Inc.Vulvovaginal Candidiasis

Start: 2015-11-30End: 2016-08-05Updated: 2019-07-12

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

CompletedNCT03253094

Scynexis, Inc.Candida Vulvovaginitis

Start: 2017-08-01End: 2018-05-04Updated: 2021-08-12

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

TerminatedNCT03672292

Scynexis, Inc.Invasive Pulmonary Aspergillosis

Start: 2019-01-22End: 2023-03-27Updated: 2024-08-09

Phase 3

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

CompletedNCT03363841

Scynexis, Inc.Candidemia, Candidiasis, Invasive

Start: 2017-11-15End: 2023-05-24Updated: 2024-07-03

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

TerminatedNCT05178862

Scynexis, Inc.Candidemia, Candidiasis, Invasive

Start: 2022-08-03End: 2025-12-16Updated: 2026-08-10

Related Papers

Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science2025-09-01

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis

Clinical Infectious Diseases2021-09-2234 citations